Jeffrey Weitz   加拿大麦克马斯特大学
    <International Circulation>:  You are involved with the experimental thrombosis and arthrosclerosis program with TARI.  Could you tell us some of the things your research institute is involved with?
   《国际循环》：您参与了实验性血栓和关节硬化方案和TARI。您能跟我们谈谈您的研究所参与的一些工作吗？
 
    Prof. Weitz:  I am the executive director of the Thrombosis and Arthrosclerosis Research Institute (TARI)， which is a university hospital research institute at McMaster University.  Within this institute there are four programs， one is the experimental thrombosis and arthrosclerosis program and other is the clinical thromboembolism program， a program that provides both clinical services to the population in the region as well as performing clinical trials related to the prevention， diagnosis and treatment of thrombosis.  We also have two other programs， a biometrics program， a statistical group which provides support for the basic science and clinical trials program， and a comparative medicine program， which investigates animal models of thrombosis and arthrosclerosis.

    Weitz教授:我是血栓和关节硬化研究学会（TARI）的执行主任，TARI是McMaster University的一个大学医院研究学会。在该研究学会中，有4个方案，一个为实验性血栓形成和关节硬化方案，另一个为向那个该地区人群提供临床服务以及进行预防、诊断和治疗血栓相关的临床试验的方案。我们还有两个其他的方案，一个生物统计学方案，一个比较医学方案，后者研究血栓和关节硬化动物模型。
    <International Circulation>:  What are some of the more interesting things to come our of TARI recently?
   《国际循环》：最近TARI有没有一些更有趣的事情？
    Prof. Weitz: ADOPT， which was a trial I was involved with， which you will hear more about today.  The BTE treatment program with tabigatran has been spearheaded by Sam Shulman， who is one of the members of our clinical thrombosis program.  The trials RECOVER I and RECOVER II， which will be presented at ASH next month， are two extended treatment studies that came out of our institute.  We are also doing basic science work as well in thrombosis and arthrosclerosis with some very interesting work published by one of our basic science researchers on the mechanism of dyslipidemia in patients with obesity showing that the adipokines and adiponectin have competing effects on LDL synthesis in the liver.  Another study on chemotherapy induced thrombosis and still other studies on catheter thrombosis with fondaparinux.  There are really lots of interesting things going on at TARI. 

    Weitz教授:ADOPT，是一个I期临床试验，今天你将听到有关它的更多报道。利用tabigatran进行 BTE治疗的方案首先由Sam Shulman报道，他是我们临床血栓形成方案的成员之一。RECOVER I和RECOVER II试验将在下个月内ASH报道，这是我们研究学会提出的两个延长治疗方案。我们也做了相关的基础研究工作，我们的基础研究人员也在血栓形成和关节硬化方面做了许多有趣的报道，他们是有关肥胖患者的血脂异常的机制，提示脂肪细胞因子和脂联素肝脏与LDL的合成油竞争作用。另一项研究是关于关于化疗导致血栓形成的研究以及其他有关fondaparinux和导管内血栓形成的研究。TARI确实又很多正在进行的有趣的研究。